

BEHAVIORAL HEALTH

Healthcare Evidence Initiative (HEI) Measure Results

- Member race and ethnicity is sourced from the California Healthcare Eligibility, Enrollment, and Retention System (CalHEERS).
- Health Evidence Initiative (HEI) data excludes Covered California for Small Business (CCSB), includes only Qualified Health Plan (QHP) submitted claims, and includes allowable adjustments resulting in small changes to measure specifications.
- Total rates are not displayed for measures stratified by race and ethnicity due to small discrepancies compared to publicly reported HEDIS and QRS measure rates, resulting from HEI data characteristics outlined above.
- All HEI-sourced rates are subject to a quality assurance process including assessing year-over-year results, comparison to QRS publicly reported results where applicable and other industry norms.
- Rates with fewer than 11 cases in the numerator have been suppressed to comply with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule's de-identification standard.
- Rates with fewer than 30 cases in the denominator have been suppressed because such small rates can be unreliable.



PHARMACOTHERAPY FOR OPIOID USE DISORDERS (NQF #3400)

	MY2017 Measure Score	MY2018 Measure Score	MY2019 Measure Score
Anthem EPO	36%	40%	43%
Blue Shield HMO	Too Few Members	28%	33%
Blue Shield PPO	34%	38%	39%
Chinese Community Health Plan HMO	Too Few Members	Too Few Members	Too Few Members
Health Net EPO	Too Few Members	Too Few Members	Too Few Members
Health Net HMO	13%	20%	23%
Health Net PPO			42%
Kaiser Permanente HMO	29%	50%	55%
LA Care HMO	Too Few Members	22%	25%
Molina Healthcare HMO	Too Few Members	Too Few Members	16%
Oscar Health Plan EPO	Too Few Members	Too Few Members	31%
Sharp Health Plan HMO	24%	21%	23%
Valley Health Plan HMO	Too Few Members	Too Few Members	Too Few Members
Western Health Advantage HMO	Too Few Members	22%	28%

- Percentage of members ages 18-64 with an Opioid Use Disorder (OUD) who got medication treatment for their opioid disorder during the measurement year
- Medication is a critical part of treatment for individuals with OUD; this measure includes the following four types of Food and Drug Administration-approved drug products:
 - Buprenorphine
 - Oral naltrexone
 - Long-acting, injectable naltrexone
 - Methadone
- Individuals who engage in treatment with medication are less likely to exhibit withdrawal or craving symptoms, and more likely to engage in mental health therapy
- Indicator: Higher is better



*Too Few Members: measure scores with numerators below 11 and/or denominators below 30.
 Blank cells indicates the health plan did not offer a product through Covered California for two consecutive years prior to measurement year.
 Please see the introductory slide to this measure for additional context.*